Savara Pharmaceuticals (Austin, TX) a development-stage Dry powder and nebulizer-based drug delivery solution, closed a $1.4M Series A financing. Participants were not identified.
Note: 2009 Year-in-Review Trend Analysis Coming 15 Feb

Zogenix (San Diego, CA) a clinical-stage drug:device company focused on a needle-free delivery system of chronic pain therapeutics, closed a $20M Series B financing, bringing the total round to $71M. Participants have included Chicago Growth Partners, Clarus Ventures, Domain Associates, Scale Venture Partners, Thomas McNerney & Partners, Oxford Finance and Abingworth Management.
Note: 2009 Year-in-Review Trend [...]

Quinnova Pharmaceuticals (Newtown, PA) a commercial-stage specialty biopharma company focused on dermatological drug reformulations and foam delivery systems, closed a $17.4M Series B financing. Participants include Safeguard Scientifics, Thomas, McNerney & Partners, H.I.G. Ventures.

Activaero (Germany) a commercial-stage medical device company focused on patient-tailored controlled breathing and inhaled therapeutic delivery systems, closed a $15.9M Series A financing. Participants include BioMedPartners, VI Partners, Abalis Finance and Vesalius Biocapital.

Zogenix (San Diego, CA) a clinical-stage drug:device company focused on a needle-free delivery system of chronic pain therapeutic, closed a $51M Series B financing. Participants include Clarus Ventures, Domain Associates, Scale Venture Partners, Thomas, McNerney & Partners, Oxford Finance and Abingworth Management.

Liquidia (Morrisville, NC) a development-stage company focused on improving delivery of inhaled therapeutics and vaccines via nanoparticles with optimized characteristics for increased target specificity, closed a $7M Series C financing. Participants include Canaan Partners, Pappas Ventures, New Enterprise Associates and Firelake Capital.

Zosano Pharma (Fremont, CA) a clinical-stage device company focused on a transdermal microprojection delivery system for needle-free administration therapeutic peptides, small molecules and vaccines. Participants include Nomura Phase4 Ventures, New Enterprise Associates, HBM BioVentures and ProQuest Investments.

Savara Pharmaceuticals (Austin, TX) a preclinical-stage developer of dry powder and nebulized-based therapeutic inhalation drug delivery platform, closed a $1.0M Series A financing. Participants were not identified.

Palyon Medical (New York, NY) a preclinical-stage medical device company focused on a spin-based drug delivery system, closed a $21M Series A financing. Participants include Baird Venture Partners, Hambrecht & Quist, Fountain Healthcare Partners, BB Biotech Ventures, Cross Atlantic Partners and Arcus Ventures.

Orthocon (North Brunswick, NJ) a preclinical-stage company focused on implantable devices that deliver therapeutics to bone, closed a $25M Series B financing. Participants include ProQuest Investments, Canaan Partners and BB Biotech Ventures.

Traversa Therapeutics (La Jolla, CA) a preclinical-stage biopharmaceutical company developing RNAi delivery technologies, closed a $5M Series B financing. Participants include Morningside, Mesa Verde Venture Partners and Tech Coast Angels.

DBV Technologies (France) a clinical-stage company developing of non-invasive epicutaneous diagnostics and immunotherapies for allergies, closed a $7.7M Series B financing. Participatnsc include ALK-Abello and Sofinnova Partners.

Chiasma (Israel) developer of Transient Permeability Enhancer technology designed to deliver proteins, peptides, polysaccharides and non-soluble small molecules into the blood to achieve clinically meaningful bioavailability levels, closed a $11M Series B financing. Participants include ARCH Venture Partners, MPM Capital, 7 Health Ventures, Ofer Hi-Tech and F2 Ventures.